| Document |
Document Title |
|
WO/2021/097057A1 |
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and c...
|
|
WO/2021/093377A1 |
In order to improve the device performance of an organic electroluminescent device, particularly the light extraction efficiency, the present application provides an organic electroluminescent device comprising a light extraction layer, ...
|
|
WO/2021/092496A1 |
Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders. Furt...
|
|
WO/2021/088756A1 |
The present invention discloses an oxime ether compound with a novel structure, wherein the structure is represented by general formula (I), and the definition of each substituent in the formula is described in the description. The compo...
|
|
WO/2021/086904A1 |
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for vascular disorders that can include, for example, retinopathies, ocular edema, and ocular neova...
|
|
WO/2021/083182A1 |
A compound of a uricosuric agent used as a uric acid transporter (URAT1) inhibitor, and application thereof in preparation of a medication for treating a disease related to abnormal uric acid levels. The present invention specifically re...
|
|
WO/2021/082997A1 |
An amide compound containing a substituted acetophenone structure fragment, having a structure shown as general formula I. Please see the description for the definitions of substituents in the formula. The compound has a broad-spectrum b...
|
|
WO/2021/073044A1 |
The present invention discloses an environment-friendly synthesis method for dibenzothiazole disulfide as rubber vulcanization accelerator, belonging to the technical field of chemical engineering. The method specifically is: completely ...
|
|
WO/2021/073643A1 |
The present application relates to the field of medicine, relates to drugs for treating non-alcoholic steatohepatitis, in particular, to linked cyclic compounds for treating non-alcoholic steatohepatitis, more in particular, to a compoun...
|
|
WO/2021/070132A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3,...
|
|
WO/2021/063880A1 |
The present invention relates to a process for the preparation 2-chloro-1-(2-chlorothiazol-5-yl)ethanone.
|
|
WO/2021/062246A1 |
Compounds are provided herein, as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).
|
|
WO/2021/058969A1 |
A composition for imaging a biological tissue or fluid comprising a compound of formula (A) and a biologically acceptable diluent or carrier, (A) wherein X represents one of a nitrogen atom, an oxygen atom, a sulphur atom, a phosphorus a...
|
|
WO/2021/061801A1 |
A genus of bicyclic inhibitors of CBX chromodomains is disclosed. The compounds are of the following genus: The compounds inhibit CBX proteins and, as a consequence, they are useful for treating prostate cancer, ovarian cancer, and B-cel...
|
|
WO/2021/062318A1 |
Provided herein are compounds of Formula (I) and Formula (II) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical composition...
|
|
WO/2021/053403A1 |
The invention provides a compound of formula (I) and processes for the manufacture of such compounds, related intermediates, compositions comprising such compounds and the use of such compounds as cytidine triphosphate synthase 1 inhibit...
|
|
WO/2021/055890A1 |
Disclosed herein are controlled release compositions comprising riluzole and the uses thereof.
|
|
WO/2021/048284A1 |
The present invention relates to a chemical compound having the general formula (I), wherein R1 is a phenyl group and R2 is a meta-substituted phenyl group; and RTA is a substituted or unsubstituted thiazole ring. The invention also rela...
|
|
WO/2021/049522A1 |
A compound represented by formula (I) or formula (II) has a pest control effect. (In the formulae, Q1 represents a pyrazine ring or the like; G1 represents a nitrogen atom or a carbon atom; X1 represents an alkyl group or the like; m rep...
|
|
WO/2021/043994A1 |
The present invention relates to an azolium compound of formula (I) and to its use as a precursor of the active catalytic species (carbene) for click chemistry reactions in water.
|
|
WO/2021/042410A1 |
Disclosed are a selective butyrylcholinesterase inhibitor having general formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof. By testing the efficacy of treatment of Alzheimer's disea...
|
|
WO/2021/032857A1 |
The invention provides the imidazole, oxazole and thiazole compounds and use thereof in methods for treating a disease or a disorder, such as infectious diseases and cancer, wherein inhibition of sphingosine-1-phosphate lyase is benefici...
|
|
WO/2021/027045A1 |
An anti-tumour compound based on JWA gene activation and HER2 degradation, a preparation method therefor, and a use thereof. The anti-tumour compound is the compound of formula I. The preparation method is using two compounds to synthesi...
|
|
WO/2021/028518A1 |
The invention relates to a new process for preparing 2-(phenylimino)-3-alkyl-1,3-thiazolidin-4-ones of the general formula (I), wherein Y1, Y2, R1, R2 and R3 have the meanings indicated in the description.
|
|
WO/2021/028375A1 |
The present invention relates to the technical field of crop protection. More specifically, the present invention relates to benazolin-choline and to compositions (formulations) comprising benazolin-choline. The invention also relates to...
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/024253A1 |
This invention is directed to a method of oxidation of 5-chloro-2-((3,4,4-trifluorobut-3- en- 1-yl)thio)- lλ3,3λ2-thiazole and analogs thereof to the corresponding sulfone, using an oxidant and a metal oxide-based catalyst.
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
|
WO/2021/024260A1 |
The technology disclosed herein concerns compounds capable of binding to CB1Rs in the periphery and not in the CNS.
|
|
WO/2021/019051A1 |
The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their thera...
|
|
WO/2021/010337A1 |
The invention is the light-emitting compound represented by formula (1), or a salt thereof.
|
|
WO/2021/010340A1 |
The present invention is a luminescent compound represented by formula (1) or a salt thereof. (In formula (1), k represents 0 or 1; at least one of X and Y represents an optionally substituted heterocyclic group containing a nitrogen ato...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/010331A1 |
The present invention is a light-emitting compound represented by formula (1) or a salt thereof.
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2021/005082A1 |
The invention relates to a process for preparing 2-(phenylimino)-1,3-thiazolidin-4-ones of the general formula (I), wherein Y1, Y2, R1, R2 and R3 have the meanings indicated in the description.
|
|
WO/2021/005081A1 |
The invention relates to a process for preparing 2-(phenylimino)-1,3-thiazolidin-4-ones of the general formula (I), wherein Y1, Y2, R1, R2 and R3 have the meanings indicated in the description.
|
|
WO/2021/004487A1 |
A thiazolidinedione derivative having the structure shown in formula (I) and a pharmaceutical composition comprising same, the definitions of each group and substituent being as described in the description. Also provided is a use of the...
|
|
WO/2021/001825A1 |
The present invention provides novel inhibitors of cystathionin gamma synthase (CGS), their use as selective and non-selective herbicides, agricultural and non-agricultural herbicides, herbicides in integrated pest management, herbicides...
|
|
WO/2020/257940A1 |
The present application provides furosemide analogues of the general formula Z having activity as anti-Aβ aggregation agents and/or as inhibitors of Aβ induced neuroinflammation. Formula Z These compounds are useful in preventing, dela...
|
|
WO/2020/262648A1 |
The present invention provides a compound that has an excellent pest-controlling effect and that is represented by formula (I) [in the formula, L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like...
|
|
WO/2020/258972A1 |
The present invention provides a brand-new hydrazone amide derivative and an application thereof in preparation of medicaments for preventing and treating alopecia. The structural formula of the hydrazone amide derivative is as shown for...
|
|
WO/2020/009492A9 |
The present specification provides a compound represented by chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2020/258893A1 |
A formulation of conjugates of tubulysin analogs with a cell-binding molecule having a structure represented by Formula (I), wherein T, L, m, n, -----, R 1, R 2, R 3, R 4, R 5, R 6, R 7, R 8, R 9, R 10, R 11, R 12, and R 13 are as define...
|
|
WO/2020/258971A1 |
Provided are a new class of hydrazone amide derivatives and the use thereof in the preparation of anti-osteoporosis drugs, wherein the structural formula of the hydrazone amide derivative is as shown in formula (I), and same are a new cl...
|
|
WO/2020/250223A1 |
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...
|
|
WO/2020/244452A1 |
A heterocyclic derivative having a β2 receptor agitation and M receptor antagonistic activity and medical use thereof. The heterocyclic derivative is a compound represented by general formula (I) or a mesomer, racemate, enantiomer, dias...
|
|
WO/2020/247819A2 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
|
WO/2020/245665A1 |
Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 ( CTPS1) inhibitors for the treatment of proliferative diseases, such as e.g. can...
|
|
WO/2020/240178A1 |
A compound, e.g. a diamine ligand, represented by the following general formula (1): (Formula (1)) wherein each * represents an asymmetric carbon atom; X represents a group selected from one of an ester (e.g. a t-butyl ester); a thioeste...
|
